Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer

  • Preclinical Study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Estrogenic steroids, such as estradiol, are known to play a crucial role in the development and growth of hormone-dependent breast cancer. Steroid sulfatase (STS) inhibitors that can prevent the biosynthesis of these steroids via the sulfatase pathway offer therapeutic potential. We show here the in vivo profile, including the efficacy in a xenograft breast cancer model and pharmacokinetics, of three potent STS inhibitors. MCF-7 cells stably over-expressing STS cDNA (MCF-7STS) were generated. Ovariectomised, MF-1, female nude mice receiving subcutaneous injections of estradiol sulfate (E2S) and bearing MCF-7STS xenografts, were orally treated with the STS inhibitors STX64, STX213, and STX1938. Treatment was administered once weekly at a dose of 1 mg/kg for 35 days during which animals received E2S thrice weekly. Mice were weighed and tumor measurements taken weekly. Furthermore, the pharmacokinetics for STX213 was determined in rats. STX213 and STX1938 exhibited potent STS inhibition in vivo. However, STX1938 demonstrated a greater duration of activity. In vehicle treated nude mice receiving E2S, tumor volumes increased by 260% after 35 days compared to day zero. STX64 (1 mg/kg) failed to reduce tumor growth when given once weekly. STX213 and STX1938 (once weekly, 1 mg/kg) significantly inhibited (P < 0.05) tumor growth over this same time period. These compounds completely inhibited liver and tumor STS activity and significantly reduced the levels of plasma E2. This study indicates that the STS inhibitor, STX213, exhibits excellent efficacy and pharmacokinetics and therefore offers a potentially novel treatment for hormone-dependent breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Cole MP, Jones CTA, Todd IDH (1971) A new antiestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46,474. Br J Cancer 25:270–275

    PubMed  CAS  Google Scholar 

  2. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 48:2431–2442

    Article  Google Scholar 

  3. Reed MJ, Purohit A, Woo LWL et al (1996) The development of steroid sulphatase inhibitors. Endocr Relat Cancer 3:9–23

    Article  CAS  Google Scholar 

  4. Reed MJ, Hutton JD, Baxendale PM et al (1979) The conversion of androstenedione to oestrone and production of oestrone in women with endometrial cancer. J Steroid Biochem 11:905–911

    Article  PubMed  CAS  Google Scholar 

  5. Falany JL, Falany CN (1996) Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res 56:1551–1555

    PubMed  CAS  Google Scholar 

  6. Falany JL, Macrina N, Falany CN (2002) Regulation of MCF-7 breast cancer cell growth by β-estradiol sulfonation. Breast Cancer Res Treat 74:167–176

    Article  PubMed  CAS  Google Scholar 

  7. Purohit A, Riaz AA, Ghilchik MW et al (1992) The origin of oestrone sulphate in normal and malignant breast tissues in postmenopausal women. Horm Metab Res 24:532–536

    PubMed  CAS  Google Scholar 

  8. Reed MJ, Purohit A, Woo LWL et al (2005) Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 26:171–202

    Article  PubMed  CAS  Google Scholar 

  9. Pasqualini JR, Chetrite G, Blacker C et al (1996) Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81:1460–1464

    Article  PubMed  CAS  Google Scholar 

  10. Bonney RC, Reed MJ, Davidson K et al (1983) The relationship between 17β-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue. Clin Endocrinol (Oxf) 19:727–739

    Article  CAS  Google Scholar 

  11. Lipton A, Santen RJ, Santner SJ et al (1992) Prognostic value of breast cancer aromatase. Cancer 70:1951–1955

    Article  PubMed  CAS  Google Scholar 

  12. Evans TR, Rowlands MG, Law M et al (1994) Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma. Br J Cancer 69:555–561

    PubMed  CAS  Google Scholar 

  13. Lonning PE, Dowsett M, Powles TJ (1990) Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 35:355–366

    Article  PubMed  CAS  Google Scholar 

  14. Evans TR, Rowlands MG, Silva MC et al (1993) Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer. J Steroid Biochem Mol Biol 44:583–587

    Article  PubMed  CAS  Google Scholar 

  15. James VHT, McNeill JM, Lai LC et al (1987) Aromatase activity in normal breast and breast tumor tissue: in vivo and in vitro studies. Steroids 50:269–279

    Article  PubMed  CAS  Google Scholar 

  16. Foster PA, Newman SP, Chander SK et al (2006) In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin Cancer Res 12:5543–5549

    Article  PubMed  CAS  Google Scholar 

  17. James MR, Skaar TC, Lee RY et al (2001) Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo. Endocrinology 142:1497–1505

    Article  PubMed  CAS  Google Scholar 

  18. Purohit A, Woo LWL, Potter BVL et al (2000) In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res 60:3394–3396

    PubMed  CAS  Google Scholar 

  19. Howarth NM, Purohit A, Reed MJ et al (1994) Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J Med Chem 37:219–221

    Article  PubMed  CAS  Google Scholar 

  20. Woo LWL, Purohit A, Malini B et al (2000) Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem Biol 7:773–791

    Article  PubMed  CAS  Google Scholar 

  21. Fischer DS, Chander SK, Woo LWL et al (2003) Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. J Steroid Biochem Mol Biol 84:343–349

    Article  PubMed  CAS  Google Scholar 

  22. Purohit A, Williams GJ, Roberts CJ et al (1995) In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int J Cancer 63:106–111

    Article  PubMed  CAS  Google Scholar 

  23. Stanway S, Purohit A, Woo LWL et al (2006) Phase I study of STX64 (667Coumate) in breast cancer: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 12:1585–1592

    Article  PubMed  CAS  Google Scholar 

  24. Seibert K, Shafie SM, Triche TJ et al (1983) Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice. Cancer Res 43:2223–2239

    PubMed  CAS  Google Scholar 

  25. Brunner N, Spang-Thomsen M, Vindelov L et al (1985) Effect of tamoxifen on the receptor-positive T61 and the receptor-negative T60 human breast carcinomas grown in nude mice. Eur J Cancer Clin Oncol 21:1349–1354

    Article  PubMed  CAS  Google Scholar 

  26. Yue W, Brodie A (1993) MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors. J Steroid Biochem Mol Biol 44:671–673

    Article  PubMed  CAS  Google Scholar 

  27. Yue W, Zhou D, Chen S et al (1994) A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 54:5092–5095

    PubMed  CAS  Google Scholar 

  28. Ireson CR, Chander SK, Purohit A et al (2004) Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats. Br J Can 91:1399–1404

    Article  CAS  Google Scholar 

Download references

Acknowledgement

This research was supported by Sterix Ltd, a member of the Ipsen Group.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College Faculty of Medicine, St Mary’s Hospital, London, W2 1NY, UK

    Paul A. Foster, Surinder K. Chander, Michael F. C. Parsons, Simon P. Newman, Michael J. Reed & Atul Purohit

  2. Medicinal Chemistry, Department of Pharmacy and Pharmacology and Sterix Ltd, University of Bath, Bath, BA2 7AY, UK

    L. W. Lawrence Woo & Barry V. L. Potter

Authors
  1. Paul A. Foster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Surinder K. Chander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael F. C. Parsons
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Simon P. Newman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. W. Lawrence Woo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Barry V. L. Potter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael J. Reed
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Atul Purohit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul A. Foster.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Foster, P.A., Chander, S.K., Parsons, M.F.C. et al. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Res Treat 111, 129–138 (2008). https://doi.org/10.1007/s10549-007-9769-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9769-3

Keywords

Search

Navigation